Report post
BMY Stock Analysis: Bristol Myers Squibb, with its robust free cash flow and attractive dividend yield, presents a compelling upside potential. Despite recent market fluctuations, the stock remains undervalued, offering investors a unique opportunity. Explore the risks and rewards of owning BMY in 2024 and decide if now is the time to buy.

The World's Leading Crypto Trading Platform

Get my welcome gifts